News
XERS
4.580
+0.88%
0.040
President & COO of Xeris Biopharma Holdings Kevin McCulloch Buys 1.5% More Shares
Simply Wall St · 1d ago
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing
Seeking Alpha · 1d ago
Top Executive Makes Bold Move with Major Stock Purchase!
TipRanks · 3d ago
Weekly Report: what happened at XERS last week (0609-0613)?
Weekly Report · 4d ago
Weekly Report: what happened at XERS last week (0602-0606)?
Weekly Report · 06/09 09:06
Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting
TipRanks · 06/04 21:48
Craig-Hallum Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)
TipRanks · 06/04 12:56
Piper Sandler Sticks to Their Hold Rating for Xeris Pharmaceuticals (XERS)
TipRanks · 06/04 10:45
Xeris Pharmaceuticals Hosts Analyst and Investor Day
TipRanks · 06/03 12:29
BRIEF-Xeris Biopharma Holdings Reaffirms 2025 Revenue Guidance Of $260-$275 Million
Reuters · 06/03 11:34
*Xeris Biopharma: XP-8121 Peak Net Rev Expected to Be $1B to $3 B Come 2035>XERS
Dow Jones · 06/03 11:32
*Xeris Biopharma Anticipates Recorlev Annual Rev of About $1 B in 2035 >XERS
Dow Jones · 06/03 11:32
XERIS BIOPHARMA HOLDINGS INC - REAFFIRMS 2025 REVENUE GUIDANCE OF $260-$275 MLN
Reuters · 06/03 11:31
*Xeris Biopharma Commits to Remaining Adjusted EBITDA Positive Going Forward >XERS
Dow Jones · 06/03 11:31
*Xeris Biopharma Expects Total Rev of About $750 M for 2030 >XERS
Dow Jones · 06/03 11:31
*Xeris Biopharma Backs FY25 Rev $260M-$275M >XERS
Dow Jones · 06/03 11:30
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
Barchart · 06/03 06:30
Xeris Biopharma to hold analyst and investor day
TipRanks · 06/02 18:00
Weekly Report: what happened at XERS last week (0526-0530)?
Weekly Report · 06/02 09:07
Catalyst Watch: Crypto buzz with the Circle IPO, Snowflake event and the May Jobs Report
Seeking Alpha · 05/30 19:00
More
Webull provides a variety of real-time XERS stock news. You can receive the latest news about Xeris Biopharma Holdings through multiple platforms. This information may help you make smarter investment decisions.
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.